Pages that link to "Q45593840"

The following pages link to Clinical and immune responses after revaccination of israeli adults with the Lister strain of vaccinia virus (Q45593840):

Displaying 20 items.

• The evolution of poxvirus vaccines (Q26995905) (← links)
• Adverse events post smallpox-vaccination: insights from tail scarification infection in mice with Vaccinia virus (Q27346800) (← links)
• Estimated size of the population at risk of severe adverse events after smallpox vaccination in Israel (Q30224090) (← links)
• Demographic and clinical factors associated with response to smallpox vaccine in preimmunized volunteers (Q30228332) (← links)
• Anticipating demand for emergency health services due to medication-related adverse events after rapid mass prophylaxis campaigns (Q30230184) (← links)
• Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection. (Q30375489) (← links)
• Effect of the deletion of genes encoding proteins of the extracellular virion form of vaccinia virus on vaccine immunogenicity and protective effectiveness in the mouse model (Q34779016) (← links)
• Smallpox vaccines: targets of protective immunity (Q34780607) (← links)
• An update on smallpox vaccine candidates and their role in bioterrorism related vaccination strategies. (Q36639156) (← links)
• Immunity from smallpox vaccine persists for decades: a longitudinal study (Q37029757) (← links)
• Rapid detection of anti-Vaccinia virus neutralizing antibodies (Q39570447) (← links)
• Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox (Q39916149) (← links)
• An open-label, single arm, phase III clinical study to evaluate the efficacy and safety of CJ smallpox vaccine in previously vaccinated healthy adults (Q42270914) (← links)
• Alternative Immunological Markers to Document Successful Multiple Smallpox Revaccinations (Q44196044) (← links)
• Complement-bound human antibodies to vaccinia virus B5 antigen protect mice from virus challenge (Q45378129) (← links)
• Tail scarification with Vaccinia virus Lister as a model for evaluation of smallpox vaccine potency in mice (Q45399764) (← links)
• Challenges and Achievements in Prevention and Treatment of Smallpox (Q47547852) (← links)
• Estimated prevalence of smallpox vaccine contraindications in Israeli adolescents (Q50851155) (← links)
• Effective post-exposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response (Q51838980) (← links)
• Diagnosis of Imported Monkeypox, Israel, 2018 (Q64073591) (← links)